Last edition
News about
Argo Biopharma Doses First Patient in Phase 1 Trial of siRNA Drug BW-50218
Argo Biopharma doses first patient in Phase 1 trial of BW-50218, an siRNA therapeutic from its RADS platform designed for potent, durable gene silencing with targeted hepatic delivery and improved safety.
AbbVie Submits FDA Application for SKYRIZI Subcutaneous Induction in Crohn's Disease
AbbVie Inc. submits an application to the US Food and Drug Administration (FDA) for SKYRIZI (risankizumab-rzaa) subcutaneous induction in Crohn’s disease, supported by Phase 3 AFFIRM data, offering a potential new treatment option.
GSK's Efimosfermin Secures FDA Breakthrough and EMA PRIME Status for MASH Treatment
The dual regulatory designations from US FDA and European Medicines Agency fast-track development of GSK’s investigational liver therapy for metabolic dysfunction-associated steatohepatitis.
Dr. Reddy's Laboratories Wins Health Canada Nod for Generic Semaglutide Injection
Dr. Reddy's Laboratories secures Health Canada approval for generic semaglutide injection, becoming the first to gain market authorisation in Canada ahead of the review timeline.
Thermo Fisher to Sell Microbiology Business to Astorg in USD 1.07 Billion Deal
Thermo Fisher’s microbiology business, which generated USD 645 million in 2025 revenue, will transition to Astorg as part of a strategic portfolio realignment.
Boston Cell Standards Advances Cancer Testing Tools into FDA Qualification Phase
Boston Cell Standards moves closer to standardising cancer diagnostics as its IHC reference tools enter FDA qualification, aiming to improve accuracy and accelerate therapy development.
U.S. Food and Drug Administration accepts sBLA for Ziihera with Priority Review, backed by Phase III data showing improved outcomes in HER2-positive advanced gastric and gastroesophageal cancers.
Soligenix Reports Phase 3 FLASH2 Interim Results for HyBryte in Cutaneous T-Cell Lymphoma
Soligenix reports Phase 3 FLASH2 interim results for HyBryte in Cutaneous T-Cell Lymphoma, with the study recommended for early termination due to futility.
Akums Launches Aztreonam-Avibactam to Combat Drug-Resistant Infections
Akums launches Aztreonam-Avibactam, an advanced antibiotic for severe drug-resistant infections, offering a new treatment option for life-threatening infections in intensive care settings.
IMG Pharma to Acquire Matsumoto Pharmaceutical
IMG Pharma signs a definitive agreement to acquire Matsumoto Pharmaceutical, combining biopharmaceutical innovation with manufacturing and OTC capabilities, forming a multi-layered product capability structure.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy